672 employees
Oxford BioMedica is a pioneer of gene and cell therapy, with a leading industry position in lentiviral vector and cell therapy research.
1995
$4.2M
from 2 investors over 2 rounds
Oxford Biomedica raised undisclosed on May 1, 2019
Investors: Novo Holdings
Oxford Biomedica raised $4.2M on January 23, 2018
Investors: Innovate UK